Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study

Hind, Daniel; Drabble, Sarah J.; Arden, Madelynne A.; Mandefield, Laura; Waterhouse, Simon; Maguire, Chin; Cantrill, Hannah; Robinson, Louisa; Beever, Daniel; Scott, Alexander J.; Keating, Sam; Hutchings, Marlene; Bradley, Judy; Nightingale, Julia; Allenby, Mark I.; Dewar, Jane; Whelan, Pauline; Ainsworth, John; Walters, Stephen J.; O’Cathain, Alicia; Wildman, Martin J.

Abstract

Preventative medication reduces hospitalisations in people with cystic fibrosis (PWCF) but adherence is poor. We assessed the feasibility of a randomised controlled trial of a complex intervention, which combines display of real time adherence data and behaviour change techniques.

Citation

Hind, D., Drabble, S. J., Arden, M. A., Mandefield, L., Waterhouse, S., Maguire, C., …Wildman, M. J. (2019). Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine, 19(1), https://doi.org/10.1186/s12890-019-0834-6

• Journal Article Type: Article
• Online Publication Date: Apr 11, 2019
• Publication Date: 2019-12
• Deposit Date: May 26, 2023
• Journal: BMC Pulmonary Medicine
• Publisher: Springer Verlag
• Peer Reviewed: Peer Reviewed
• Volume: 19
• Issue: 1
• DOI: https://doi.org/10.1186/s12890-019-0834-6
• Keywords: Pulmonary and Respiratory Medicine
• Additional Information: Received: 6 July 2018; Accepted: 20 March 2019; First Online: 11 April 2019; : Written informed consent was obtained prior to participation. The study received ethical approval from the London Brent Research Ethics Committee (16/LO/0356).; : Not applicable.; : Martin Wildman received funding from Zambon and support from Philips Respironics for the early intervention development work. This has not had any direct influence on the feasibility study reported here. In addition, Martin Wildman has worked with Pari to carry out studies using the e-track. This has not had any direct influence on the feasibility study reported here. The University of Manchester software team received funding from Pari to create a medication reporting component within the CFHealthHub software. This has not had any direct influence on the feasibility study reported here.The other authors declare that they have no competing interests.; : Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.